Anthem (NASDAQ:ANTX – Get Free Report) is one of 224 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Anthem to related companies based on the strength of its profitability, dividends, institutional ownership, analyst recommendations, risk, valuation and earnings.
Analyst Ratings
This is a summary of recent recommendations and price targets for Anthem and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anthem | 1 | 0 | 1 | 0 | 2.00 |
| Anthem Competitors | 2223 | 2459 | 4371 | 67 | 2.25 |
Anthem currently has a consensus target price of $2.00, indicating a potential downside of 53.92%. As a group, “Pharmaceutical preparations” companies have a potential upside of 149.43%. Given Anthem’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Anthem has less favorable growth aspects than its rivals.
Risk and Volatility
Profitability
This table compares Anthem and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anthem | N/A | -55.04% | -49.13% |
| Anthem Competitors | -4,803.12% | -250.26% | -48.16% |
Earnings & Valuation
This table compares Anthem and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Anthem | N/A | -$35.17 million | -3.74 |
| Anthem Competitors | $333.00 million | -$26.93 million | -4.54 |
Anthem’s rivals have higher revenue and earnings than Anthem. Anthem is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
90.5% of Anthem shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 24.5% of Anthem shares are owned by insiders. Comparatively, 14.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Anthem rivals beat Anthem on 7 of the 13 factors compared.
Anthem Company Profile
Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Receive News & Ratings for Anthem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthem and related companies with MarketBeat.com's FREE daily email newsletter.
